Join Us

Interested in working at the Center? Check out our job opportunities page.

Contact the Center

Administrative Contact:
Barbara Dearry

You are here: Home / Research / Centers / Center for Integrative Chemical Biology and Drug Discovery

Center for Integrative Chemical Biology and Drug Discovery

The Center for Integrative Chemical Biology and Drug Discovery was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic chemists, assay development and compound profiling scientists will work in the Center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process.  The Center provides leadership of the North Carolina Comprehensive Chemical Biology Center, a member of NCI's Chemical Biology Consortium.

Research & Funding News

"Identification of a Fragment-like Small Molecule Ligand for the Methyl-lysine Binding Protein, 53BP1" published by Perfetti et al. online in ACS Chemical Biology, January 15, 2015.

Stephen Frye and CICBDD featured in the University Gazette October 29, 2014.  Read More  See Video

Center receives $3 million to support research through a gift to the School of Pharmacy from Dr. Fred Eshelman.  More

Center collaborator J. Coghill, MD, awarded translational research grant from the Leukemia & Lymphoma Society.  Read More

The Center has moved into the newly opened Marsico Hall at 125 Mason Farm Road, Chapel Hill, NC 27599-7363. More

"UNC 2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor" published by W. Zhang et al., J. Med. Chem. 2014 57, 7031-7041.

"The Lipid Kinase PIP5K1C Regulates Pain Signaling and Sensitization" published in Neuron, 82 (4) 836-847 with Collaborator Mark Zylka and team. 

The Melanoma Research Alliance and the Saban Family Foundation announce Team Science Award to conduct study: "TAMs in melanoma: Mechanisms and therapeutic efficacy of novel inhibitors.”  Award funds collaboration with Hebrew University, University of Colorado Anschutz Medical Campus, and UNC researchers in the CICBDD and Lineberger Comprehensive Cancer Center.  More

A Chemical Tool for in vitro and in vivo Precipitation of the Lysine Methyltransferase G9a published by Jin group and collaborators in ChemMedChem, 2014, DOI: 10.1002/cmdc.201300450.  View inside cover image by Kyle Konze and Samantha Pattenden.

Bill Janzen and collaborator Cyrus Vaziri (lead PI) receive NIH grant targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy.   Read More

Erythropoietin Promotes Breast Tumorigenesis Through Tumor Initiating Cell Self-renewal published by Jian Jin and collaborators in J. Clin. Investig. 2014, DOI: 10.1172/JCI69804. 

Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors  published by Weihe Zhang et al., in J. Med. Chem. 2013, 56, 9683-9692.

Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis published by Weihe Zhang et al.  in J. Med. Chem.  2013, 56, 9693-9700.

Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3 published by Lindsey James et al. in J. Med. Chem., Article ASAP,  DOI: 10.1021/jm400919p,  online Sept. 16, 2013.

Camerino, MA et al. The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface, MedChemComm 4, 1501-7 (2013). DOI: 10.1039/C3MD00197K,  published online 17 Sep 2013.

Chemical probe for the L3MBTL3 methyllysine reader domain featured on cover of Nature Chemical Biology, January 2013. See paper by Lindsey James et al. in collaboration with the Structural Genomics Consortium and U. Toronto.    Article Cover See also ESOP feature.

Efficient Solution-Phase Synthesis of 4,5,7-Trisubstituted Pyrrolo[3,2-d]pyrimidines published by Weihe Zhang et al. in ACS Combinatorial Science, 2013, 15 (1), pp 10–19.

Document Actions